Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia

Meghann Mcmanus, Haydar Frangoul, Jonathan Mccullers, Li Wang, Alice O'Shea, Natasha Halasa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Although children with acute lymphoblastic leukemia (ALL) mount immune responses after vaccination with the trivalent influenza vaccine (TIV), these responses are lower compared to controls. Recently, a high dose (HD) TIV was found to increase the level of antibody response in elderly patients compared to the standard dose (SD) TIV. We hypothesized that the HD TIV would be well-tolerated and more immunogenic compared to the SD TIV in pediatric subjects with ALL. Procedure: This was a randomized, double-blind, phase I safety trial comparing the HD to the SD TIV in children with ALL. Our secondary objective was immunogenicity. Subjects were randomized 2:1 to receive either the HD (60μg) or the SD (15μg) TIV. Local and systemic reactions were solicited, hemagglutinin inhibition titers to influenza virus antigens were measured, and monitoring labs were collected prior to and/or after each vaccination. Results: Fifty subjects were enrolled (34 HD, 16 SD). Mean age was 8.5 years; 63% were male, and 80% were in maintenance therapy. There were no significant differences reported in local or systemic symptoms. No severe adverse events were attributed to vaccination. No significant differences between the HD and SD TIV groups were noted for immune responses. Conclusions: No differences were noted between the HD and SD TIV groups for solicited systemic and local reactions. Since this study was not powered for immunogenicity, a phase II trial is needed to determine the immunogenicity of HD versus SD TIV in the pediatric ALL population. Pediatr Blood Cancer 2014;61:815-820.

Original languageEnglish (US)
Pages (from-to)815-820
Number of pages6
JournalPediatric Blood and Cancer
Volume61
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Inactivated Vaccines
Influenza Vaccines
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Safety
Vaccination
Hemagglutinins
Orthomyxoviridae
Antibody Formation
Antigens

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. / Mcmanus, Meghann; Frangoul, Haydar; Mccullers, Jonathan; Wang, Li; O'Shea, Alice; Halasa, Natasha.

In: Pediatric Blood and Cancer, Vol. 61, No. 5, 01.01.2014, p. 815-820.

Research output: Contribution to journalArticle

Mcmanus, Meghann ; Frangoul, Haydar ; Mccullers, Jonathan ; Wang, Li ; O'Shea, Alice ; Halasa, Natasha. / Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 5. pp. 815-820.
@article{a34d239f78a844339e91f8e319eab570,
title = "Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia",
abstract = "Background: Although children with acute lymphoblastic leukemia (ALL) mount immune responses after vaccination with the trivalent influenza vaccine (TIV), these responses are lower compared to controls. Recently, a high dose (HD) TIV was found to increase the level of antibody response in elderly patients compared to the standard dose (SD) TIV. We hypothesized that the HD TIV would be well-tolerated and more immunogenic compared to the SD TIV in pediatric subjects with ALL. Procedure: This was a randomized, double-blind, phase I safety trial comparing the HD to the SD TIV in children with ALL. Our secondary objective was immunogenicity. Subjects were randomized 2:1 to receive either the HD (60μg) or the SD (15μg) TIV. Local and systemic reactions were solicited, hemagglutinin inhibition titers to influenza virus antigens were measured, and monitoring labs were collected prior to and/or after each vaccination. Results: Fifty subjects were enrolled (34 HD, 16 SD). Mean age was 8.5 years; 63{\%} were male, and 80{\%} were in maintenance therapy. There were no significant differences reported in local or systemic symptoms. No severe adverse events were attributed to vaccination. No significant differences between the HD and SD TIV groups were noted for immune responses. Conclusions: No differences were noted between the HD and SD TIV groups for solicited systemic and local reactions. Since this study was not powered for immunogenicity, a phase II trial is needed to determine the immunogenicity of HD versus SD TIV in the pediatric ALL population. Pediatr Blood Cancer 2014;61:815-820.",
author = "Meghann Mcmanus and Haydar Frangoul and Jonathan Mccullers and Li Wang and Alice O'Shea and Natasha Halasa",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/pbc.24863",
language = "English (US)",
volume = "61",
pages = "815--820",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia

AU - Mcmanus, Meghann

AU - Frangoul, Haydar

AU - Mccullers, Jonathan

AU - Wang, Li

AU - O'Shea, Alice

AU - Halasa, Natasha

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Although children with acute lymphoblastic leukemia (ALL) mount immune responses after vaccination with the trivalent influenza vaccine (TIV), these responses are lower compared to controls. Recently, a high dose (HD) TIV was found to increase the level of antibody response in elderly patients compared to the standard dose (SD) TIV. We hypothesized that the HD TIV would be well-tolerated and more immunogenic compared to the SD TIV in pediatric subjects with ALL. Procedure: This was a randomized, double-blind, phase I safety trial comparing the HD to the SD TIV in children with ALL. Our secondary objective was immunogenicity. Subjects were randomized 2:1 to receive either the HD (60μg) or the SD (15μg) TIV. Local and systemic reactions were solicited, hemagglutinin inhibition titers to influenza virus antigens were measured, and monitoring labs were collected prior to and/or after each vaccination. Results: Fifty subjects were enrolled (34 HD, 16 SD). Mean age was 8.5 years; 63% were male, and 80% were in maintenance therapy. There were no significant differences reported in local or systemic symptoms. No severe adverse events were attributed to vaccination. No significant differences between the HD and SD TIV groups were noted for immune responses. Conclusions: No differences were noted between the HD and SD TIV groups for solicited systemic and local reactions. Since this study was not powered for immunogenicity, a phase II trial is needed to determine the immunogenicity of HD versus SD TIV in the pediatric ALL population. Pediatr Blood Cancer 2014;61:815-820.

AB - Background: Although children with acute lymphoblastic leukemia (ALL) mount immune responses after vaccination with the trivalent influenza vaccine (TIV), these responses are lower compared to controls. Recently, a high dose (HD) TIV was found to increase the level of antibody response in elderly patients compared to the standard dose (SD) TIV. We hypothesized that the HD TIV would be well-tolerated and more immunogenic compared to the SD TIV in pediatric subjects with ALL. Procedure: This was a randomized, double-blind, phase I safety trial comparing the HD to the SD TIV in children with ALL. Our secondary objective was immunogenicity. Subjects were randomized 2:1 to receive either the HD (60μg) or the SD (15μg) TIV. Local and systemic reactions were solicited, hemagglutinin inhibition titers to influenza virus antigens were measured, and monitoring labs were collected prior to and/or after each vaccination. Results: Fifty subjects were enrolled (34 HD, 16 SD). Mean age was 8.5 years; 63% were male, and 80% were in maintenance therapy. There were no significant differences reported in local or systemic symptoms. No severe adverse events were attributed to vaccination. No significant differences between the HD and SD TIV groups were noted for immune responses. Conclusions: No differences were noted between the HD and SD TIV groups for solicited systemic and local reactions. Since this study was not powered for immunogenicity, a phase II trial is needed to determine the immunogenicity of HD versus SD TIV in the pediatric ALL population. Pediatr Blood Cancer 2014;61:815-820.

UR - http://www.scopus.com/inward/record.url?scp=84895739693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895739693&partnerID=8YFLogxK

U2 - 10.1002/pbc.24863

DO - 10.1002/pbc.24863

M3 - Article

VL - 61

SP - 815

EP - 820

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -